Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Biologic therapy.

Duke University Medical Center, Durham, NC, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Durham, NC
Treatments:Chemotherapy, Biologic therapyHospital:Duke University Medical Center
Drugs:Journal:Link
Date:May 2011

Description:

Patients:
This study involved 25 patients with recurrent glioblastoma, who had received prior bevacizumab treatment. The median age of the group was 52 years and 68% were male.

Treatment:
Patients were treated with the chemotherapy agents carboplatin and irinotecan, as well as the biologic therapy agent bevacizumab.

Toxicities:
The maximum toxicity level reported was grade 4, including neutropenia and thrombocytopenia. Grade 3 fatigue, hypertension, and anemia were also reported.

Results:
The median overall survival was 5.8 months.

Support:
This study was partially funded by Genetech, makers of bevacizumab.

Correspondence: Dr. David A. Reardon; email: [email protected]



Back